A Study of Selpercatinib (LY3527723) in Participants With Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer
← catalyst calendarSponsored by Eli Lilly and Company (industry) · LLY — their whole pipeline →. With Loxo Oncology, Inc..
Phase
Phase 3
Status
Active, not recruiting
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
261actual
Sites
196
Countries
Argentina, Australia, Belgium +23
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2020-02-17 | actual | When the study began enrolling |
| Primary completion | 2023-05-01 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Jun 2030 | estimated | The whole study's end, after follow-up |
| First posted | 2019-12-11 | actual | When this record first appeared on the registry |
| Results posted | 2024-06-20 | actual | When the sponsor posted results to the registry |
| Record updated | 2025-10-21 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Non-Small Cell Lung Cancer
Interventions
- Drug: Selpercatinib — also filed as LY3527723, LOXO-292
- Drug: Carboplatin
- Drug: Cisplatin
- Drug: Pemetrexed
- Drug: Pembrolizumab
Primary outcomes
what the primary-completion date above is the date OFProgression Free Survival (PFS) by Blinded Independent Central Review (BICR) (With Pembrolizumab)
measured Baseline to Progressive Disease or Death from Any Cause Up to 31 Months
PFS by BICR (With or Without Pembrolizumab)
measured Baseline to Progressive Disease or Death from Any Cause Up to 31 Months
Posted documents
hosted by the registry — we link, never re-serveStudy Protocolposted 2023-08-15 · 1.3 MB · Prot_000.pdf
Statistical Analysis Planposted 2023-04-27 · 3.0 MB · SAP_001.pdf
Publications
- PMID 41996652 — linked by the registry
- PMID 38828957 — linked by the registry
- PMID 37870973 — linked by the registry
- PMID 35378489 — linked by the registry
- PMID 33150799 — linked by the registry
Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.
Permalink · LLY's whole pipeline · Catalyst calendar · Every registered study · What changed